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Efl'ect of chronic human recombinant erythropoietin therapy on anti.
body responses to immunization in chronic hemodialysis patients. There
are multiple lines of evidence suggesting that human recombinant eryth-
ropoietin (rEPO) could influence immune responses by direct effects of
rEPO on T or B cells. The present study tested this hypothesis by
measuring antibody responses after immunization to tetanus toxoid (TI, a
T cell dependent antigen) or pneumococcal capsular polysaccharide
antigen (PA, a T cell independent antigen). The patients chosen for this
prospective study were chronic hemodialysis patients receiving chronic
rEPO therapy, and a comparable group of chronic hemodialysis patients
not receiving rEPO therapy. We found that the patients immunized with
PA and receiving rEPO therapy (N = 15) had IgG anti-PA responses
comparable to that of those not receiving rEPO therapy (N = 15). In
contrast, in the patients immunized with TI, those receiving rEPO (N =
15) developed significantly higher TgG anti-U levels than those not
receiving rEPO (N = 14) (time-group interaction P = 0.005). The peak
difference between these groups was at two weeks, where the rEPO-
treated patients developed a 4.1-fold mean increase in IgG anti-TT level
and those not receiving rEPO developed only a 1.4-fold mean increase in
IgG anti-IT level (P < 0.01). The difference in immune response to IT in
the rEPO compared to the non-rEPO-treated patients could not be
explained by differences between the groups in any of the parameters
measured at baseline or during the post-immunization period. In conclu-
sion, rEPO therapy increased immune response to IT but not PA, which
suggests that rEPO enhances immune response to T cell dependent
antigens.
There are multiple lines of evidence which suggest that rEPO,
one of the most widely used therapies in renal failure, may
influence immune responses because of effects of rEPO on cells of
the humoral and cellular immune system. In vitro studies have
shown that rEPO increases B cell production of immunoglobulins
independent of effects of rEPO on T cells [1, 2]. In vitro studies
have also shown that in vitro production of IgE by B cells is
increased by rEPO through an effect of rEPO on T cells [31.
Studies in patients have shown that rEPO therapy may decrease
the absolute number of circulating T cells but increase the ratio of
T helper to T suppressor cells [4—6]. In vitro studies have also
shown that rEPO increases the proliferation of a broad spectrum
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of bone marrow progenitor cells [7]. The biological significance of
these findings, however, is not clear.
The single study that attempted to examine in vivo responses to
rEPO therapy by testing antibody responses to immunization to
hepatitis B vaccine, a T cell dependent antigen, found that
antibody responses were five- to eightfold higher in the rEPO-
treated dialysis patients compared to the dialysis patients not
receiving rEPO [4]. However, the results of that study are difficult
to interpret because the study is retrospective. In addition, the
patients who did not receive rEPO therapy received significantly
more blood transfusions than did the rEPO-treated patients, both
prior to and during the period of immunization with hepatitis B
vaccine. Blood transfusion can suppress immune responses [re-
viewed in 4]. Thus, the weaker immune response to hepatitis B
vaccine in the non-rEPO-treated patients of that study might have
been the result of blood transfusions, not the lack of rEPO.
The present investigation is a prospective study in which the
rEPO-treated patients were matched to the non-rEPO-treated
patients with respect to age, gender, duration on dialysis, and
diabetic versus nondiabetic renal status. In addition, blood trans-
fusion in these patients during the course of this eight week study
was minimal, and not significantly different among the experimen-
tal groups. Thus, the present study provides the clearest evidence
to date as to whether or not chronic rEPO therapy influences
immune responses.
Methods
Patients selected for this study were those who were either
initiating chronic hemodialysis treatments or were established
chronic hemodialysis patients at The Ohio State University Med-
ical Center, the Biomedical Applications (BMA)-Central Ohio
Dialysis Center (CODC)-North, BMA-CODC-East, BMA-
CODC-Grant Park, Doctor's Hospital West, and Mt. Carmel
Medical Center West. All patients were judged to be clinically
stable and in a satisfactory state of health and nutrition. Patients
were excluded from study if they were receiving immunosuppres-
sive medications (prednisone, azathioprine, cyclophosphamide,
chiorambucil, or cyclosporine A) or had evidence of infection with
human immunodeficiency virus (HIV), hypersensitivity to tetanus
toxoid (TT) or pneumococcal capsular polysaccharide antigen
(PA) vaccines, or had received these vaccines in the past 5 or 10
years, respectively.
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Table 1. Baseline clinical characteristics of the patient groups
Groups N
Gender
male/female
Race
black/white
Age°
years
Dialysis
years
Diabetic
N
rEptY
Units
PA° 15 9/6 3/12 61 12 1.7 2.6 6 —
EPO/PAb 15 10/5 4/11 64 14 1.9 2.1 4 3607 1567
TT' 14 9/5 5/9 56 18 2.2 4.1 6
EPorvrd 15 9/6 7/8 56 14 2.6 3.8 6 3639 1905
a Immunization with PA, no rEPO therapy
b Immunization with PA during rEPO therapy
Immunization with IT, no rEPO therapy
d Immunization with IT during rEPO therapy
a Mean so
Until start of study, mean SD
gAdministered at each hemodialysis treatment SD
The patients recruited into this study who were not receiving
rEPO therapy but generally maintained hemoglobin levels above
8 gIdl without the need for blood transfusions. As these patients
were recruited into the study, we surveyed the chronic hemodial-
ysis populations at the collaborating dialysis centers and selected
for recruitment those who were receiving rEPO therapy and: (1)
met the inclusion and exclusion criteria of the study, and (2)
matched the non-rEPO-treated patients with respect to age (± 5
years), gender, race, duration on dialysis (> 1 year or < 1 year),
and cause of renal failure (diabetic or nondiabetic renal disease).
As the non-rEPO patients were recruited into the study, they
were assigned on an alternating basis to receive either TT or PA.
When the rEPO-treated patient matching the non-rEPO-treated
patient was recruited into the study, the rEPO-treated patient
received the same immunization as that assigned to the non-
rEPO-treated patient. If the patients participated in the TT
immunization portion of the study, they did not participate in the
PA immunization portion of the study, and vice versa.
All patients receiving rEPO were tested and prior to rEPO
therapy were shown to have adequate levels of B12 and folic acid.
During rEPO therapy, all patients received iron supplementation,
usually ferrous sulfate 325 mg one to three times daily. rEPO
doses in individual patients ranged from 1,500 to 8,000 units and
were given intravenously at the termination of each hemodialysis
treatment, which was usually three times weekly.
Immunization protocol
The patients were immunized according to the manufacturer's
instruction. For both TT immunization (Wyeth, Marietta, PA,
USA) and PA immunization (Pnu-Imune; Lederle, Pearl River,
NY, USA), 0.5 ml of vaccine was injected subcutaneously in the
deltoid muscle just prior to initiating hemodialysis and the
infusion of heparin. The blood samples were obtained before
heparin infusion (week 0) by drawing 7 ml of blood into vacu-
tamer tubes containing EDTA. The blood tubes were then placed
on ice at 4°C. In each patient, blood samples were also obtained
at two, four, six, and eight weeks after immunization. All blood
samples were separated from cells within 24 hours. The plasma
was stored at —70°C until analysis of the antibody levels.
Analytic studies
Routine laboratory studies were performed by the hospital
laboratories of the hospitals of the respective dialysis centers or by
the BMA clinical laboratory (North Vale, NJ, USA).
Total IgG anti-TIE' and anti-PA antibody levels were measured
using commercially available enzyme immunoassays (The Binding
Site Inc., San Diego, CA, USA). Briefly, plasma samples were
thawed from —70°C and were diluted between 1/400 and 1/4000 in
the provided diluent. For measurement of anti-PA antibody
levels, antibodies to noncapsular C-polysaccharide were absorbed
by inclusion of purified C-polysaccharide in the diluent. One
hundred microliters of each diluted plasma sample were added in
duplicate to wells of 96 well plates containing coated TF or PA,
and were incubated at room temperature for 30 minutes. The
plasma samples were removed, the wells were washed three times
with diluent, and 100 Ll of horseradish peroxidase-conjugated
sheep anti-human IgG antibody was added. After 30 minutes at
room temperature, the conjugate was removed, and the wells were
washed three times. Positive samples were detected after the
addition of tetramethylbenzidine by measuring optical density at
450 nm. Human serum samples with known anti-IT and anti-PA
antibody levels were used to generate standard curves to calculate
the concentration of specific antibody in each patient plasma
sample (j.tg/ml plasma).
Data analysis
The data were analyzed using repeated measures analysis of
covariance (ANOVA) controlling for the baseline value. First, the
differences between the PA groups and between the IT groups
were analyzed using repeated measures ANOVA with missing
data points. An additional repeated measure was run controlling
for baseline values, using only patients in the IT groups for whom
complete data were available. This test excluding patients with
missing values was necessary in order to generate the mean square
error values required to perform the t-tests between groups at
various times.
Results
Patient population
Table 1 shows the baseline clinical characteristics of the patient
groups. As can be seen, the experimental groups were compara-
ble. There were no significant differences in these baseline
parameters between the experimental groups.
Tables 2, 3, 4, and 5 show selected individual laboratory values
and therapies for the patients in the experimental groups. The
individual values are shown so that the baseline laboratory results
and therapies can be compared to each patient's own immune
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Table 2. Group PA: Individual laboratory parametersa and therapies
Name Hb" HctC BUNd SCrC SAIb1 CCBh ACEi' Calcitrol
JUMA 7.2 22.5 64 16.7 3.9 63 Y Y 2.0
LEMI 8.2 27.6 97 6.4 2.9 85 Y N 0
DOMA 8.7 27.5 62 6.8 3.1 38 Y N 0
IRDE 7.7 23.2 49 7.8 3.4 72 N N 1.0
ROTR 10.3 36.7 71 12.9 3.8 40 N N 1.0
LODO 8.5 29.1 48 — — 31 Y Y 0
RODI 9.4 27.9 50 10.6 — — Y N 0
MIGE 8.4 26.3 — — — — N N 0
ALDA 8.4 26.3 63 5.9 3.1 31 Y N 2.0
JEAN 11.2 34.3 77 3.0 3.7 55 Y N 1.25
ABEG 7.9 23.4 64 9.8 3.9 48 Y N 0.5
LODE — — — — — — N N 0
URPA — — — — — — N N 0
CLSU 7.1 21.7 50 5.2 3.5 27 Y N 0.25
ROCA 8.7 27.6 50 9.1 3.6 49 Y N 0.50
X SE 8.6 0.3 27.2 1.2 62 4 8.6 1.1 3.5 0.11 49 5.3 0.57 0.19
a Laboratory results obtained 31 days or less before immunization
"Blood hemoglobin, gidi
C Blood hematocrit, %
d Blood urea nitrogen, mgldl
C Serum creatinine, mg/dl
Serum albumin, gidi
g Serum ferritin, mg/dl
h Calcium channel blockers therapy, yes (Y) or no (N)
Angiotension converting enyzeme inhibition therapy
pg at each hemodialysis treatment
Table 3. Group EPO/PA: Individual laboratory parameters' and therapies
Name Hbb HctC BUNd SCrC SA,b1 CCBh ACEi Calcitrol'
PAST 6.8 22.8 55 10.2 2.6 14 N N 1.0
NOHA 8.5 29.3 38 7.9 3.1 41 N N 1.5
ROJO 11.4 37.1 67 13.4 3.7 38 Y N 1.0
MAKA 10.6 34.1 63 4.0 3.7 43 N N 0.25
DOMC 9.8 29.9 63 5.0 3.5 53 Y Y 0.50
ROOL 9.4 29.1 89 13.4 3.9 76 N N 0.25
EMTH 6.5 22.2 35 4.9 2.0 42 N Y 1.0
CLCA 7.5 24.9 63 11.0 4.0 16 N N 0.50
GLEA 8.2 26.4 63 4.3 3.6 67 N N 1.0
MIHO 8.7 27.3 108 14.1 3.8 34 N N 0.50
RUJO 11.0 35.7 53 1.9 3.5 61 N Y 1.0
JEMC 8.3 25.4 83 8.4 3.7 40 N N 0.5
ROWA 10.2 32.1 66 12.0 4.3 43 Y N 2.0
NODO 8.9 27.4 52 10.2 3.7 46 N N 0.50
RISM 9.9 32.3 24 6.4 3.4 77 N Y 0.50
X SE 9 0.37 29.1 1.1 62 5 8.5 1 3.5 0.14 46 4.6 0.80 0.13
a Laboratory results obtained 31 days or less before immunization
"Blood hemoglobin, gidi
C Blood hematocrit, %
d Blood urea nitrogen, mg/dI
Serum creatinine, mg/dl
Serum albumin, g/dl
g Serum ferritin, mg/dl
h Calcium channel blockers therapy, yes (Y) or no (N)
Angiotension converting enyzeme inhibition therapy
'.tg at each hemodialysis treatment
responses. There were no significant differences between the be seen, rEPO therapy did not significantly influence antibody
experimental groups except for a higher mean calcitriol dose in responses to immunization with PA. The dose of rEPO at baseline
the group EPO/TT compared to the group IT. did not correlate with the magnitude of the anti-PA response (at
2 weeks, r =
—0.062, P = 0.833).
Immunization with PA
Table 6 shows the sequential anti-PA IgG levels in each of the Immunization with TT
patients in the rEPO and non-rEPO groups. Figure 1 shows the Table 7 shows the sequential anti-IT IgG levels in each of the
mean anti-PA IgG level for these groups during the study. As can patients in the rEPO and non-rEPO groups. Figure 2 shows the
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Table 4. Group TT: Individual laboratory parametersa and therapies
Name Hbb HctC BUNd SCrC SAIh3 CCB5 ACEi' Calcitrol
ANAL 10.2 32.3 68 13.7 4.5 31 Y N 050
SAPA 8.3 27.8 50 6.9 4.2 58 Y Y 0
CLSW 11.1 32.2 75 10.9 3.6 — N N 0.50
CHRA 11.6 36.6 78 17.2 3.7 47 N N 0
GESL 9.4 31.1 68 5.2 3.6 40 N N 0
ERBU 8.2 24.8 66 7.3 — — N N 0
MIGI 6.2 20.1 68 15.4 3.2 47 N N 1.0
DOSP 9.2 30.7 41 5.8 — — N N 1.0
MAMI 8.6 27.4 49 7.3 3.3 30 N N 0
DOWH 8.7 26.6 88 9.0 4.4 70 Y N 0.25
TEHI 8.4 27.2 36 9.9 3.7 53 Y N 0.50
ROPE 10.5 33.9 66 4.5 2.8 25 Y N 0
CHRY 11.1 34.3 57 5.9 — — N N 0
EDMO — — — — — — N N 1.0
X SE 9.3 0.4 29.6 1.2 62 4 9.1 1.1 3.7 0.16 45 5 0.34 011k
Laboratory results obtained 31 days or less before immunization
b Blood hemoglobin, gidi
C Blood hematocrit, %
d Blood urea nitrogen, mg/dl
C Serum creatinine, mgldl
Serum albumin, gidi
g Serum ferritin, mg!dl
' Calcium channel blockers therapy, yes (Y) or no (N)
Angiotension converting enyzeme inhibition therapy
g at each hemodialysis treatment
P = 0.024 compared to calcitriol dose in group EPO/Ti'
Table 5. Group EPOITF: Individual laboratory parameters' and therapies
Name Hbb Hct' BUNd SCrC 5AIb SFCC CCBh ACEi Calcitrol
MACA 10.1 33.6 59 8.2 3.6 73 Y Y 0.50
EDDA 7.9 27.3 99 7.3 7.6 15 N N 1.5
CENA 9.2 31.6 67 5.6 3.2 11 N N 0.50
WIRE 10.4 33.8 45 12.1 4.2 136 N N 0.5
EURO 10.3 32.8 82 16.8 3.5 85 N N 1.0
MEBU 9.5 30.4 71 10.4 3.6 21 N N 0
WIDA 8.6 27.5 42 7.3 3.5 16 Y N 0.50
MIDO 7.8 24.5 48 7.4 3.2 60 N N 1.0
MEMA 9.9 31.4 48 10.1 3.7 48 Y N 2.0
WIPA 9.0 26.9 58 12.9 4.0 86 N N 0.50
VISU 7.4 21.7 111 15.4 4.2 74 N N 0.50
PAWI 10.4 32 60 11.9 3.9 51 N N 0
PAEC 9.9 31.9 134 33.4 4.0 35 N N 0.50
MAGR 9.6 30.8 110 9.3 3.9 28 Y N 1.25
MABO 9.3 30.4 74 7.5 3.5 51 Y N 1.5
X SE 9.3 0.24 29.8 0.9 74 7 11.7 1.7 3.9 0.3 53 9 0.78 0.15
a Laboratory results obtained 31 days or less before immunization
b Blood hemoglobin, gidi
C Blood hematocrit, %
d Blood urea nitrogen, mg/dl
C Serum creatinine, mg/dl
Serum albumin, gIdi
gSerum ferritin, mg/dl
"Calcium channel blockers therapy, yes (Y) or no (N)
Angiotension converting enyzeme inhibition therapy
'g at each hemodialysis treatment
mean anti-TT IgG level for these two groups during the study. As
can be seen, the IgG response to IT in the patients receiving
rEPO rose to the peak value more quickly than those not
receiving rEPO, and this numerical difference was sustained over
the eight weeks of the study. Statistical analysis showed that the
IgG anti-TI' levels over the course of the study were higher in
those who received rEPO compared to those who did not receive
rEPO (group-time interaction P = 0.005). Testing at specific time
points showed a significant difference between groups at two
weeks (P < 0.01) but not at later time points.
The results shown in Figure 2 were generated using all of the
data points in Table 7, including patients with missing data points.
Because of the significant differences found between these groups,
an additional analysis was performed excluding those patients
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Weeks post-immunization
Fig. 1. Mean anti-PA levels (pg/mi plasma) in PA-immunized chronic
dialysis patients receiving ( ) or not receiving (----) rEPO.
The relationship between certain therapies and antibody re-
sponse was examined because of the evidence that calcium
channel blockers [8], ACE inhibitors [9], and calcitriol [10] can
influence immune cells. There were no differences between
experimental groups in the use of calcium channel blockers or
ACE inhibitors. As noted above, the mean calcitriol dose was
slightly higher in the group EPO/TT compared to the group TT
only. However, in the group EPO/TT, there was no correlation
between calcitriol dose and antibody response.
Blood transfusions were enumerated from six months prior to
the study up to the end of the study. A single blood transfusion
was received by each of two patients in group rEPO/PA, one
patient in the group IT, and one patient in the EPO group
rEPO/TI'.
______
General clinical outcomes
The patients tolerated the immunizations well. No adverse
consequences of the immunization were noted, except for some
patients who experienced a few days of mild swelling and pain at
the site of immunization. During the course of the study, no
events were recorded on the outpatient record that could be
expected to influence immune responses. Of the scheduled 295
blood tests, 288 (98%) were obtained on schedule during the
patients' usual outpatient dialysis routine.
Discussion
The present study shows that rEPO therapy had no apparent
influence on the antibody responses of chronic hemodialysis
patients immunized with PA, a T cell independent antigen [11]. By
contrast, the patients receiving rEPO and immunized to Ti', a T
cell dependent antigen 12], showed more prompt and higher
increases in antibody levels to Ti', than those not receiving rEPO.
The differences in antibody response to Ti' and the lack of
differences in antibody response to PA could not be explained by
any of the parameters measured at baseline or during the conduct
of the study. Thus, we conclude that rEPO enhances B cell
responses to Ti' apparently because of effects of rEPO on T cell
dependent immune responses. The results of the present study are
consistent with that of the prior study that retrospectively exam-
ined the immune response to hepatitis B vaccine, a T cell
dependent antigen, and showed an increased specific antibody
response in those receiving rEPO [4].
Table 6. Anti-PA IgG levels during the 8 week period following PA
immunization 900
800
. 700
600
500
400
300
200
100
0
0 2 4 6
Name
Anti-PA IgG pg/mlplasma at week
0 2 4 6 8
Group PA
JUMA 132 283 ND 449 481
LEMI 9 66 ND 136 108
DOMA 40 ND 191 210 191
IRDE 139 96 142 96 145
ROTR 53 357b 713 ND 681
LODO 73 869 1256 1227 1070
RODI 100 159 189 170 182
MIGE 35 145 191b 205 220
ALDA 96 4189 3484b 2767b 3405
JEAN 18 419b 424 325 230
ABEG 42 1503 2410 2355 2302
LODE 21 220 378 438 ND
URPA 12 220 449 ND ND
CLSU 14 459 470 356 300
ROCA 15 33 50 71 65
Mean 53 644 796 677 722
Group EPO/PA
PAST 121 1316 1315 1173 1101
NOHA 9 18 16 24" 25
ROJO 145 492 553 580 713
MAKA 6 6 6 7 6
DOMC 136 191 196 210 215
ROOL 100 998 1094 1146 1070
EMTH 70 230 238 215 149
CLCA 36 1154 1325 1387 1325
GLEA 44 175 225 220 210
MIHO 32 2005 2832 3105 3648
RUJO 39 1265 1592 1871 1294
JEMC 45 290 382 303 258
ROWA 57 475 424 409 400
NODO 132 126 145 152 139
RISM 100 65 96 94 119
Mean 71 587 696 726 712
8
The patient groups are as defined in Table 1.
aNot done
Data measured from samples obtained one week of scheduled
blood draw
with missing data points (only 2 patients were excluded from each
group) and the means were adjusted for differences in baseline
anti-ri' levels. Analysis of these adjusted means also showed a
significant difference in anti-Ti' levels between the groups overall
(P = 0.030, time-group interaction) and at two weeks (P = 0.01).
The dose of rEPO at baseline did not significantly correlate
with the magnitude of the anti-FT response (at 2 weeks, r = 0.370,
P = 0.193).
Relationship between baseline parameters and responses to
immunization
Within experimental groups there was no statistically significant
correlation between a given baseline parameter and antibody
levels measured at two weeks, except for a positive correlation
between the serum creatinine level and antibody level in the group
EPO/TT. However, this correlation was largely accounted for by
the results in a single patient (PAEC) who had a very high serum
creatinine level and a very high antibody response.
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poietin therapy could enhance this process. This hypothesis was
not tested in the present study.
If, as the present data suggest, rEPO enhances T cell functions
under conditions in which T cell function is depressed (chronic
hemodialysis patients are known to have suppressed T cell
function [17, 181), the clinical significance of the present observa-
tion could be substantial. For example, rEPO therapy might
benefit patients with infection and depressed T cell function.
Conversely, rEPO therapy in patients with allografts might pre-
dispose to allograft rejection. However, a small study suggests that
rEPO therapy prior to renal transplantation does not adversely
affect renal outcome [191.
In summary, this is the first prospective, controlled trial of the
effect of rEPO on immune responses. Significant improvement by
rEPO of antibody responses to IT, a T cell dependent antigen, is
demonstrated. The mechanism and clinical significance of this
observation remain to be explored.
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